CD274 and non-small cell lung carcinoma: In a French multicenter retrospective study, hyperprogressive disease was observed in pretreated patients with advanced NSCLC who received PD-1/PD-L1 inhibitors or single agent chemotherapy in 13.8% and 5.1%, respectively [31].